Skip to main content

Table 4 Treatment patterns among patients with metastatic NSCLC with a subsequent therapy

From: EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Subsequent therapyPatients who received 1 L EGFR-TKI and had subsequent therapyPatients who received 2 L+ EGFR-TKI and had subsequent therapy
(N = 160)(N = 134)
Chemotherapy alone, n (%)25 (15.6)29 (21.6)
Immunotherapy alone, n (%)22 (13.8)55 (41.0)
Targeted therapies n (%)a112 (70.0)49 (36.6)
EGFR-TKIb102 (63.8)33 (24.6)
Continued on/switched to another 1st/2nd gen. EGFR-TKI62 (38.8)27 (20.1)
Afatinib33 (20.6)11 (8.2)
Erlotinib17 (10.6)13 (9.7)
Gefitinib13 (8.1)5 (3.7)
Osimertinibc40 (25.0)7 (5.2)
Other targeted therapiesd10 (6.3)16 (11.9)
Clinical study drug, n (%)1 (0.6)1 (0.7)
  1. 1 L first line, 2 L+ second or later line, ALK anaplastic lymphoma kinase EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, NSCLC non-small cell lung cancer
  2. a Patients could have received targeted therapies alone or in combination with chemotherapy and/or immunotherapy
  3. b Four patients had more than one EGFR-TKI as a subsequent therapy. Hence, the sum of the individual EGFR-TKIs (i.e. afatinib, erlotinib, geftinib, and osimertinib) will be greater than the total number who received EGFR-TKI
  4. c Of the 47 patients who received osimertinib as subsequent therapies, 24 were tested T790M positive, seven were not positive for T790M, and 16 were not tested for EGFR mutations
  5. d Other targeted therapeutic agents are listed in Table 1